Related Experiment Video

Updated: Feb 24, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

39.6K

Telmisartan ameliorates adipoR1 and adipoR2 expression via PPAR-γ activation in the coronary artery and VSMCs

Xuhua Shen1, Hongwei Li1, Weiping Li1

  • 1Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, West district, Beijing 100050, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|August 25, 2017
PubMed

Insights

Telmisartan treatment improved insulin resistance and reduced inflammation in diabetic rats. It upregulated adiponectin receptors (AdipoRs) in the coronary artery and vascular smooth muscle cells by activating PPAR-γ.

Area of Science:

  • Cardiovascular Pharmacology
  • Metabolic Syndrome Research

Background:

  • Coronary artery disease is a common complication of diabetes, characterized by insulin resistance and inflammation.
  • Adiponectin receptors (AdipoRs) play a crucial role in regulating glucose and lipid metabolism, and their dysregulation is implicated in insulin resistance.

Purpose of the Study:

  • To investigate the effects of telmisartan on insulin resistance and adiponectin receptor expression in a diabetic rat model.
  • To elucidate the underlying mechanisms involving peroxisome proliferator-activated receptor-gamma (PPAR-γ) in the coronary artery and vascular smooth muscle cells.

Main Methods:

  • A diabetic rat model was induced using a high-fat diet and streptozotocin.
  • Primary rat coronary vascular smooth muscle cells (VSMCs) were treated with high glucose.
  • Telmisartan, GW1929 (PPAR-γ agonist), and GW9662 (PPAR-γ antagonist) were administered to assess their effects on insulin resistance, inflammation markers (TNF-α), and AdipoR1/R2 expression.

Main Results:

  • Telmisartan treatment ameliorated insulin resistance, weight gain, hypertension, and hypertriglyceridemia in diabetic rats.
  • Telmisartan increased plasma adiponectin and decreased TNF-α expression in the coronary artery.
  • Telmisartan and GW1929 upregulated AdipoR1 and AdipoR2 expression in VSMCs, an effect blocked by GW9662, indicating PPAR-γ activation.

Conclusions:

  • Telmisartan effectively ameliorates coronary insulin resistance and inflammation in diabetic rats.
  • Telmisartan upregulates AdipoR1 and AdipoR2 expression via PPAR-γ activation in the coronary artery and VSMCs.
  • These findings highlight telmisartan's potential therapeutic role in managing diabetic cardiovascular complications.
Keywords:
Adiponectin receptorsDiabeticPPAR-γTelmisartan

More Related Videos

Differentiation and Imaging of Brown Adipocytes from the Stromal Vascular Fraction of Interscapular Adipose Tissue from Newborn Mice04:46

Differentiation and Imaging of Brown Adipocytes from the Stromal Vascular Fraction of Interscapular Adipose Tissue from Newborn Mice

Published on: February 3, 2023

2.4K
An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

4.3K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
506
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
476
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K